Phase I clinical trial of CO17-1A monoclonal antibody.

Authors

Albert LoBuglio, University Of Alabama At Birmingham, USA
Mansoor Saleh, Aga Khan University, USAFollow
Peterson L, University Of Alabama At Birmingham, USA
Wheeler R, University Of Alabama At Birmingham, USA
Carrano R, University Of Alabama At Birmingham, USA
Huster W, University Of Alabama At Birmingham, USA

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

Twenty patients with metastatic gastrointestinal cancer received one or more weekly infusions of 400 mg CO17-1A monoclonal antibody. The most common side effect was mild gastrointestinal symptoms in 9/20 patients. Two of five patients receiving three weekly infusions had reversible anaphylactic reactions at the time of their third infusion. The pharmacokinetics of the antibody were similar at the first, second or third infusion. Human antibody to 17-1A occurred in 17/20 patients with 11/20 having antibody detectable by 8 days following initial infusion. Thus, one or two infusions (weekly) of large doses of 17-1A were well tolerated but allergic responses limit ability to administer therapy by 15 days post-initial infusion.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Hybridoma

Recommended Citation

LoBuglio, A., Saleh, M., L, P., R, W., R, C., W, H. (1986). Phase I clinical trial of CO17-1A monoclonal antibody.. Hybridoma, 5, 117-123.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/156